Harmony Biosciences Holdings, Inc.
HRMY
$38.05
$0.882.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 772.53M | 744.85M | 714.73M | 681.88M | 656.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 772.53M | 744.85M | 714.73M | 681.88M | 656.11M |
| Cost of Revenue | 167.33M | 161.33M | 156.82M | 145.56M | 135.08M |
| Gross Profit | 605.19M | 583.53M | 557.92M | 536.32M | 521.03M |
| SG&A Expenses | 238.58M | 230.31M | 221.27M | 219.56M | 209.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 550.67M | 549.81M | 523.91M | 506.58M | 478.02M |
| Operating Income | 221.86M | 195.04M | 190.83M | 175.30M | 178.09M |
| Income Before Tax | 225.14M | 197.20M | 191.80M | 175.34M | 165.00M |
| Income Tax Expenses | 44.24M | 44.48M | 46.31M | 52.71M | 50.01M |
| Earnings from Continuing Operations | 180.90 | 152.72 | 145.49 | 122.63 | 114.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 180.90M | 152.72M | 145.49M | 122.63M | 114.99M |
| EBIT | 221.86M | 195.04M | 190.83M | 175.30M | 178.09M |
| EBITDA | 245.73M | 218.99M | 214.94M | 199.56M | 202.50M |
| EPS Basic | 3.16 | 2.68 | 2.56 | 2.15 | 1.98 |
| Normalized Basic EPS | 2.46 | 2.16 | 2.11 | 1.92 | 1.88 |
| EPS Diluted | 3.10 | 2.62 | 2.51 | 2.11 | 1.95 |
| Normalized Diluted EPS | 2.41 | 2.12 | 2.07 | 1.89 | 1.85 |
| Average Basic Shares Outstanding | 228.75M | 228.08M | 227.54M | 228.76M | 231.76M |
| Average Diluted Shares Outstanding | 233.27M | 232.39M | 231.46M | 232.10M | 234.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |